Login to Your Account



Mix of Good, Bad News for ImClone's Erbitux at ASCO

By Donna Young


Tuesday, June 3, 2008
While data from the much-anticipated FLEX Phase III study showed that ImClone Systems Inc.'s Erbitux (cetuximab) prolonged life by about five weeks for patients with non-small-cell lung cancer (NSCLC), findings from another study of the drug in colorectal cancer showed that patients with the KRAS gene mutation were unlikely to benefit from Erbitux. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription